Eupraxia Pharmaceuticals, Inc. · TSX:EPRX
Eupraxia Pharmaceuticals — United European Gastroenterology Week 2026
15 slides from Eupraxia Pharmaceuticals's conference presentation, Oct 17, 2026
Slide 1: Improvements in Histopathological Features of EoE Following Single Administration of EP-104GI
Improvements in Histopathological Features of Eosinophilic Esophagitis Following a Single Administration of EP-104GI During Dose Escalation in the Phase 1b/2 RESOLVE Study Margaret H. Collins,1 Nam Nguyen,2 Vincent Ho,3 Hin Hin Ko,4 Waqqas Afif,5 Gerald Holtmann,6 Evan S. Dellon,7 Pranali Ravikumar,
Slide 2: The Eosinophilic Esophagitis (EoE) Inflammatory Cascade
The Eosinophilic Esophagitis (EoE) Inflammatory Cascade o Esophageal inflammation and progressive structural Potential Mode of Action of EP-104GI remodeling in EoE can lead to dysphagia and food In Eosinophilic Esophagitis impaction.1 o Currently systemic and topical treatment options recommended in
Slide 3: RESOLVE: Phase 1b/2 Dose-Escalation and Optimization Trial of EP-104GI in EoE
RESOLVE (NCT05608681): Phase 1b/2 Multicenter, Open-Label, Dose- Escalation and Optimization Trial of EP-104GI In EoE Phase 1b - Dose Escalation Portion Aims to determine the safety, tolerability, PK and dose/pattern of administration of EP-104GI o EP-104GI was administered in dose cohorts of Cohort
Slide 4: Baseline Demographics & Characteristics
Baseline Demographics & Characteristics o Baseline demographics, histology, and symptom scores were overall balanced between dose cohorts RESOLVE Phase 1b – Baseline Demographics And Characteristics (full analysis set) * 4 x 1 mg 8 x 1 mg 8 x 2.5 mg 12 x 2.5 mg 12 x 4 mg 16 x 4 mg 20 x 4 mg 20 x 6 m
Slide 5: No Dose-Limiting Toxicities Observed During Dose Escalation
No Dose-Limiting Toxicities Observed During Dose Escalation o Injections were escalated between cohorts from 4 to 20 injections with no observed dose-limiting toxicities. o EP-104GI was safe and well tolerated to date for all dose cohorts, with no drug-related serious adverse events. RESOLVE Phase 1
Slide 6: EoE Histological Score System (EoEHSS) Assesses Disease Histopathology
EoE Histological Score System (EoEHSS) Assesses Disease Histopathology Features of EoE Histological Score System EoEHSS Inflammatory Features o Assesses histopathological features of EoE:1 o Grade (severity) Eosinophilic Surface o Stage (extent) Layering (ESL) Structural o Based on 8 features (each
Slide 7: Mean Change From Baseline in EoEHSS After EP-104GI Administration
EoE Histology Scoring System (EoEHSS) After EP-104GI Administration Mean Change From Baseline In EoEHSS 20 x 4mg 20 x 6mg 20 x 6mg 20 x 8mg o EoEHSS was assessed at (cohort 7) (cohort 8) (cohort 8b) (cohort 9) the 4 worst affected biopsy 0.1 Week Week Week Week locations, based on Peak 4 12 36 ‡ 4 1
Slide 8: EoEHSS Sub Scores After EP-104GI Administration
EoEHSS Sub Scores After EP-104GI Administration Mean Change From Baseline In EoEHSS Sub Scores 20 x 4mg 20 x 6mg 20 x 6mg 20 x 8mg (cohort 7) (cohort 8) (cohort 8b) (cohort 9) 0.1 ‡ W4 W12 W36 W4 W12 W36 ‡ W12 W36 W4 W12 W36 Mean Change From Baseline W4 0.0 Inflammatory -0.1 o Overall improvements i
Slide 9: EoEHSS Inflammatory Features After EP-104GI Administration
EoEHSS Inflammatory Features After EP-104GI Administration o Eosinophil-dependant features (inflammation (EI), abscesses (EA) and surface layering (ESL)) show numerical improvements over 36 weeks following a single EP-104GI administration o Surface epithelial alteration (SEA) demonstrate more pronou
Slide 10: EoEHSS Structural Features After EP-104GI Administration
EoEHSS Structural Features After EP-104GI Administration o Basal Zone Hyperplasia (BZH) and Dilated Intercellular Space (DIS) show the most consistent improvements across all four doses o Lamina Propria Fibrosis (LPF) saw improvements in cohorts 20×6mg (8b) and 20×8mg (9) 20 x 4mg 20 x 6mg (cohort 7
Slide 11: Conclusions – Phase 1b Part of RESOLVE
Conclusions – Phase 1b Part of RESOLVE Dose escalation of EP-104GI has been safe, and well tolerated to date, with no signs of dose-limiting toxicities or treatment-related adverse events. These results demonstrate consistent long-term improvements from baseline in eosinophilic and non-eosinophilic
Slide 12: Appendix
Appendix 11
Slide 13: EP-104GI is Administered in a Single Procedure, at Baseline
EP-104GI is Administered in a Single Procedure, at Baseline EP-104GI Injection Patterns in Phase 1b Dose Escalation in RESOLVE o EP-104GI was injected in the esophagus submucosa during endoscopy with a through-the-scope injector o Injected in alternating quadrants in levels separated by 2 cm o EP-10
Slide 14: EoEHSS Score & Sub Scores Baseline Values
EoEHSS Score & Sub Scores Baseline Values (mean ±sd) 4 x 1mg 8 x 1mg 8 x 2.5mg 12 x 2.5mg 12 x 4mg 16 x 4mg 20 x 4mg 20 x 6mg 20 x 6mg 20 x 8mg (cohort 1) (cohort 2) (cohort 3) (cohort 4) (cohort 5) (cohort 6) (cohort 7) (cohort 8) (cohort 8b) (cohort 9) Grade 0.55 ±0.04 0.60 ±0.08 0.32 ±0.24 0.65 ±
Slide 15: EoEHSS Features Baseline Values
EoEHSS Features Baseline Values (mean ±sd) 4 x 1mg 8 x 1mg 8 x 2.5mg 12 x 2.5mg 12 x 4mg 16 x 4mg 20 x 4mg 20 x 6mg 20 x 6mg 20 x 8mg (cohort 1) (cohort 2) (cohort 3) (cohort 4) (cohort 5) (cohort 6) (cohort 7) (cohort 8) (cohort 8b) (cohort 9) Inflammatory Features Grade 2.67 ±0.58 3.00 ±0.00 2.00
Eupraxia Pharmaceuticals — United European Gastroenterology Week 2026 on 6ix